King's College London

Research portal

Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT

Research output: Contribution to journalArticlepeer-review

Standard

Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT. / Goldstein, Laura; Robinson, Emily J.; Pilecka, Izabela et al.

In: Health Technology Assessment, Vol. 25, No. 43, 01.06.2021, p. vii-144.

Research output: Contribution to journalArticlepeer-review

Harvard

Goldstein, L, Robinson, EJ, Pilecka, I, Perdue, I, Mosweu, I, Read, J, Jordan, H, Wilkinson, M, Rawlings, G, Feehan, S, Callaghan, H, Day, E, Purnell, J, Baldellou Lopez, M, Brockington, A, Burness, C, Poole, N, Eastwood, C, Moore, M, Mellers, JDC, Stone, J, Carson, A, Medford, N, Reuber, M, McCrone, P, Murray, J, Richardson, M, Landau, S & Chalder, T 2021, 'Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT', Health Technology Assessment, vol. 25, no. 43, pp. vii-144. https://doi.org/10.3310/hta25430

APA

Goldstein, L., Robinson, E. J., Pilecka, I., Perdue, I., Mosweu, I., Read, J., Jordan, H., Wilkinson, M., Rawlings, G., Feehan, S., Callaghan, H., Day, E., Purnell, J., Baldellou Lopez, M., Brockington, A., Burness, C., Poole, N., Eastwood, C., Moore, M., ... Chalder, T. (2021). Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT. Health Technology Assessment, 25(43), vii-144. https://doi.org/10.3310/hta25430

Vancouver

Goldstein L, Robinson EJ, Pilecka I, Perdue I, Mosweu I, Read J et al. Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT. Health Technology Assessment. 2021 Jun 1;25(43):vii-144. https://doi.org/10.3310/hta25430

Author

Goldstein, Laura ; Robinson, Emily J. ; Pilecka, Izabela et al. / Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT. In: Health Technology Assessment. 2021 ; Vol. 25, No. 43. pp. vii-144.

Bibtex Download

@article{db355d7dd55f470cae7ec5314ba0be1a,
title = "Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT",
abstract = "BACKGROUND: Dissociative (non-epileptic) seizures are potentially treatable by psychotherapeutic interventions; however, the evidence for this is limited. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of dissociative seizure-specific cognitive-behavioural therapy for adults with dissociative seizures. DESIGN: This was a pragmatic, multicentre, parallel-arm, mixed-methods randomised controlled trial. SETTING: This took place in 27 UK-based neurology/epilepsy services, 17 liaison psychiatry/neuropsychiatry services and 18 cognitive-behavioural therapy services. PARTICIPANTS: Adults with dissociative seizures in the previous 8 weeks and no epileptic seizures in the previous year and meeting other eligibility criteria were recruited to a screening phase from neurology/epilepsy services between October 2014 and February 2017. After psychiatric assessment around 3 months later, eligible and interested participants were randomised between January 2015 and May 2017. INTERVENTIONS: Standardised medical care consisted of input from neurologists and psychiatrists who were given guidance regarding diagnosis delivery and management; they provided patients with information booklets. The intervention consisted of 12 dissociative seizure-specific cognitive-behavioural therapy 1-hour sessions (plus one booster session) that were delivered by trained therapists, in addition to standardised medical care. MAIN OUTCOME MEASURES: The primary outcome was monthly seizure frequency at 12 months post randomisation. The secondary outcomes were aspects of seizure occurrence, quality of life, mood, anxiety, distress, symptoms, psychosocial functioning, clinical global change, satisfaction with treatment, quality-adjusted life-years, costs and cost-effectiveness. RESULTS: In total, 698 patients were screened and 368 were randomised (standardised medical care alone, n = 182; and cognitive-behavioural therapy plus standardised medical care, n = 186). Primary outcome data were obtained for 85% of participants. An intention-to-treat analysis with multivariate imputation by chained equations revealed no significant between-group difference in dissociative seizure frequency at 12 months [standardised medical care: median of seven dissociative seizures (interquartile range 1-35 dissociative seizures); cognitive-behavioural therapy and standardised medical care: median of four dissociative seizures (interquartile range 0-20 dissociative seizures); incidence rate ratio 0.78, 95% confidence interval 0.56 to 1.09; p = 0.144]. Of the 16 secondary outcomes analysed, nine were significantly better in the arm receiving cognitive-behavioural therapy at a p-value < 0.05, including the following at a p-value ≤ 0.001: the longest dissociative seizure-free period in months 7-12 inclusive post randomisation (incidence rate ratio 1.64, 95% confidence interval 1.22 to 2.20; p = 0.001); better psychosocial functioning (Work and Social Adjustment Scale, standardised treatment effect -0.39, 95% confidence interval -0.61 to -0.18; p < 0.001); greater self-rated and clinician-rated clinical improvement (self-rated: standardised treatment effect 0.39, 95% confidence interval 0.16 to 0.62; p = 0.001; clinician rated: standardised treatment effect 0.37, 95% confidence interval 0.17 to 0.57; p < 0.001); and satisfaction with treatment (standardised treatment effect 0.50, 95% confidence interval 0.27 to 0.73; p < 0.001). Rates of adverse events were similar across arms. Cognitive-behavioural therapy plus standardised medical care produced 0.0152 more quality-adjusted life-years (95% confidence interval -0.0106 to 0.0392 quality-adjusted life-years) than standardised medical care alone. The incremental cost-effectiveness ratio (cost per quality-adjusted life-year) for cognitive-behavioural therapy plus standardised medical care versus standardised medical care alone based on the EuroQol-5 Dimensions, five-level version, and imputed data was £120,658. In sensitivity analyses, incremental cost-effectiveness ratios ranged between £85,724 and £206,067. Qualitative and quantitative process evaluations highlighted useful study components, the importance of clinical experience in treating patients with dissociative seizures and potential benefits of our multidisciplinary care pathway. LIMITATIONS: Unlike outcome assessors, participants and clinicians were not blinded to the interventions. CONCLUSIONS: There was no significant additional benefit of dissociative seizure-specific cognitive-behavioural therapy in reducing dissociative seizure frequency, and cost-effectiveness over standardised medical care was low. However, this large, adequately powered, multicentre randomised controlled trial highlights benefits of adjunctive dissociative seizure-specific cognitive-behavioural therapy for several clinical outcomes, with no evidence of greater harm from dissociative seizure-specific cognitive-behavioural therapy. FUTURE WORK: Examination of moderators and mediators of outcome. TRIAL REGISTRATION: Current Controlled Trials ISRCTN05681227 and ClinicalTrials.gov NCT02325544. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 43. See the NIHR Journals Library website for further project information.",
author = "Laura Goldstein and Robinson, {Emily J.} and Izabela Pilecka and Iain Perdue and Iris Mosweu and Julie Read and Harriet Jordan and Matthew Wilkinson and Gregg Rawlings and Sarah Feehan and Hannah Callaghan and Elana Day and James Purnell and {Baldellou Lopez}, Maria and Alice Brockington and Christine Burness and Norman Poole and Carole Eastwood and Michele Moore and Mellers, {John DC} and Jon Stone and Alan Carson and Nick Medford and Markus Reuber and Paul McCrone and Joanna Murray and Mark Richardson and Sabine Landau and Trudie Chalder",
note = "Funding Information: Declared competing interests of authors: Alan Carson reports being a paid editor of the Journal of Neurology, Neurosurgery and Psychiatry, and is the director of a research programme on functional neurological disorders; he gives independent testimony in court on a range of neuropsychiatric topics (50% pursuer, 50% defender). Sabine Landau is a paid editor of the Journal of Child Psychology and Psychiatry. Markus Reuber is the paid editor-in-chief of Seizure – European Journal of Epilepsy and receives authorship fees from Oxford University Press (Oxford, UK) in relation to a number of books about dissociative seizures. Markus Reuber benefited from the support of the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (Translational Neuroscience). Mark P Richardson reports funding from Xenon Pharma (Burnaby, BC, Canada). Jon Stone reports independent expert testimony work for personal injury and medical negligence claims, royalties from UpToDate for articles on functional neurological disorders and runs a free non-profit self-help website, www.neurosymptoms.org. Jon Stone is also supported by an NHS Scotland NHS Research Scotland (NRS) Career Fellowship. Jon Stone and Alan Carson also acknowledge the financial support of NHS Research Scotland through the Edinburgh Clinical Research Facility. Laura Goldstein, Trudie Chalder and Sabine Landau report support from the NIHR Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. Emily J Robinson received salary support from the NIHR Biomedical Research Centre based at Guy{\textquoteright}s and St Thomas{\textquoteright} NHS Foundation Trust and King{\textquoteright}s College London. Gregg Rawlings is entitled to authorship fees from Oxford University Press for several books on dissociative seizures. Funding Information: Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 43. See the NIHR Journals Library website for further project information. Funding Information: The research reported in this issue of the journal was funded by the HTA programme as project number 12/26/01. The contractual start date was in June 2014. The draft report began editorial review in April 2020 and was accepted for publication in August 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors{\textquoteright} report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Publisher Copyright: {\textcopyright} 2021 Goldstein et al. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jun,
day = "1",
doi = "10.3310/hta25430",
language = "English",
volume = "25",
pages = "vii--144",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "NIHR Journals Library",
number = "43",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Cognitive behavioural therapy compared with standardised medical care for adults with dissociative non-epileptic seizures: the CODES RCT

AU - Goldstein, Laura

AU - Robinson, Emily J.

AU - Pilecka, Izabela

AU - Perdue, Iain

AU - Mosweu, Iris

AU - Read, Julie

AU - Jordan, Harriet

AU - Wilkinson, Matthew

AU - Rawlings, Gregg

AU - Feehan, Sarah

AU - Callaghan, Hannah

AU - Day, Elana

AU - Purnell, James

AU - Baldellou Lopez, Maria

AU - Brockington, Alice

AU - Burness, Christine

AU - Poole, Norman

AU - Eastwood, Carole

AU - Moore, Michele

AU - Mellers, John DC

AU - Stone, Jon

AU - Carson, Alan

AU - Medford, Nick

AU - Reuber, Markus

AU - McCrone, Paul

AU - Murray, Joanna

AU - Richardson, Mark

AU - Landau, Sabine

AU - Chalder, Trudie

N1 - Funding Information: Declared competing interests of authors: Alan Carson reports being a paid editor of the Journal of Neurology, Neurosurgery and Psychiatry, and is the director of a research programme on functional neurological disorders; he gives independent testimony in court on a range of neuropsychiatric topics (50% pursuer, 50% defender). Sabine Landau is a paid editor of the Journal of Child Psychology and Psychiatry. Markus Reuber is the paid editor-in-chief of Seizure – European Journal of Epilepsy and receives authorship fees from Oxford University Press (Oxford, UK) in relation to a number of books about dissociative seizures. Markus Reuber benefited from the support of the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (Translational Neuroscience). Mark P Richardson reports funding from Xenon Pharma (Burnaby, BC, Canada). Jon Stone reports independent expert testimony work for personal injury and medical negligence claims, royalties from UpToDate for articles on functional neurological disorders and runs a free non-profit self-help website, www.neurosymptoms.org. Jon Stone is also supported by an NHS Scotland NHS Research Scotland (NRS) Career Fellowship. Jon Stone and Alan Carson also acknowledge the financial support of NHS Research Scotland through the Edinburgh Clinical Research Facility. Laura Goldstein, Trudie Chalder and Sabine Landau report support from the NIHR Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King’s College London. Emily J Robinson received salary support from the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. Gregg Rawlings is entitled to authorship fees from Oxford University Press for several books on dissociative seizures. Funding Information: Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 43. See the NIHR Journals Library website for further project information. Funding Information: The research reported in this issue of the journal was funded by the HTA programme as project number 12/26/01. The contractual start date was in June 2014. The draft report began editorial review in April 2020 and was accepted for publication in August 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Publisher Copyright: © 2021 Goldstein et al. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/6/1

Y1 - 2021/6/1

N2 - BACKGROUND: Dissociative (non-epileptic) seizures are potentially treatable by psychotherapeutic interventions; however, the evidence for this is limited. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of dissociative seizure-specific cognitive-behavioural therapy for adults with dissociative seizures. DESIGN: This was a pragmatic, multicentre, parallel-arm, mixed-methods randomised controlled trial. SETTING: This took place in 27 UK-based neurology/epilepsy services, 17 liaison psychiatry/neuropsychiatry services and 18 cognitive-behavioural therapy services. PARTICIPANTS: Adults with dissociative seizures in the previous 8 weeks and no epileptic seizures in the previous year and meeting other eligibility criteria were recruited to a screening phase from neurology/epilepsy services between October 2014 and February 2017. After psychiatric assessment around 3 months later, eligible and interested participants were randomised between January 2015 and May 2017. INTERVENTIONS: Standardised medical care consisted of input from neurologists and psychiatrists who were given guidance regarding diagnosis delivery and management; they provided patients with information booklets. The intervention consisted of 12 dissociative seizure-specific cognitive-behavioural therapy 1-hour sessions (plus one booster session) that were delivered by trained therapists, in addition to standardised medical care. MAIN OUTCOME MEASURES: The primary outcome was monthly seizure frequency at 12 months post randomisation. The secondary outcomes were aspects of seizure occurrence, quality of life, mood, anxiety, distress, symptoms, psychosocial functioning, clinical global change, satisfaction with treatment, quality-adjusted life-years, costs and cost-effectiveness. RESULTS: In total, 698 patients were screened and 368 were randomised (standardised medical care alone, n = 182; and cognitive-behavioural therapy plus standardised medical care, n = 186). Primary outcome data were obtained for 85% of participants. An intention-to-treat analysis with multivariate imputation by chained equations revealed no significant between-group difference in dissociative seizure frequency at 12 months [standardised medical care: median of seven dissociative seizures (interquartile range 1-35 dissociative seizures); cognitive-behavioural therapy and standardised medical care: median of four dissociative seizures (interquartile range 0-20 dissociative seizures); incidence rate ratio 0.78, 95% confidence interval 0.56 to 1.09; p = 0.144]. Of the 16 secondary outcomes analysed, nine were significantly better in the arm receiving cognitive-behavioural therapy at a p-value < 0.05, including the following at a p-value ≤ 0.001: the longest dissociative seizure-free period in months 7-12 inclusive post randomisation (incidence rate ratio 1.64, 95% confidence interval 1.22 to 2.20; p = 0.001); better psychosocial functioning (Work and Social Adjustment Scale, standardised treatment effect -0.39, 95% confidence interval -0.61 to -0.18; p < 0.001); greater self-rated and clinician-rated clinical improvement (self-rated: standardised treatment effect 0.39, 95% confidence interval 0.16 to 0.62; p = 0.001; clinician rated: standardised treatment effect 0.37, 95% confidence interval 0.17 to 0.57; p < 0.001); and satisfaction with treatment (standardised treatment effect 0.50, 95% confidence interval 0.27 to 0.73; p < 0.001). Rates of adverse events were similar across arms. Cognitive-behavioural therapy plus standardised medical care produced 0.0152 more quality-adjusted life-years (95% confidence interval -0.0106 to 0.0392 quality-adjusted life-years) than standardised medical care alone. The incremental cost-effectiveness ratio (cost per quality-adjusted life-year) for cognitive-behavioural therapy plus standardised medical care versus standardised medical care alone based on the EuroQol-5 Dimensions, five-level version, and imputed data was £120,658. In sensitivity analyses, incremental cost-effectiveness ratios ranged between £85,724 and £206,067. Qualitative and quantitative process evaluations highlighted useful study components, the importance of clinical experience in treating patients with dissociative seizures and potential benefits of our multidisciplinary care pathway. LIMITATIONS: Unlike outcome assessors, participants and clinicians were not blinded to the interventions. CONCLUSIONS: There was no significant additional benefit of dissociative seizure-specific cognitive-behavioural therapy in reducing dissociative seizure frequency, and cost-effectiveness over standardised medical care was low. However, this large, adequately powered, multicentre randomised controlled trial highlights benefits of adjunctive dissociative seizure-specific cognitive-behavioural therapy for several clinical outcomes, with no evidence of greater harm from dissociative seizure-specific cognitive-behavioural therapy. FUTURE WORK: Examination of moderators and mediators of outcome. TRIAL REGISTRATION: Current Controlled Trials ISRCTN05681227 and ClinicalTrials.gov NCT02325544. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 43. See the NIHR Journals Library website for further project information.

AB - BACKGROUND: Dissociative (non-epileptic) seizures are potentially treatable by psychotherapeutic interventions; however, the evidence for this is limited. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of dissociative seizure-specific cognitive-behavioural therapy for adults with dissociative seizures. DESIGN: This was a pragmatic, multicentre, parallel-arm, mixed-methods randomised controlled trial. SETTING: This took place in 27 UK-based neurology/epilepsy services, 17 liaison psychiatry/neuropsychiatry services and 18 cognitive-behavioural therapy services. PARTICIPANTS: Adults with dissociative seizures in the previous 8 weeks and no epileptic seizures in the previous year and meeting other eligibility criteria were recruited to a screening phase from neurology/epilepsy services between October 2014 and February 2017. After psychiatric assessment around 3 months later, eligible and interested participants were randomised between January 2015 and May 2017. INTERVENTIONS: Standardised medical care consisted of input from neurologists and psychiatrists who were given guidance regarding diagnosis delivery and management; they provided patients with information booklets. The intervention consisted of 12 dissociative seizure-specific cognitive-behavioural therapy 1-hour sessions (plus one booster session) that were delivered by trained therapists, in addition to standardised medical care. MAIN OUTCOME MEASURES: The primary outcome was monthly seizure frequency at 12 months post randomisation. The secondary outcomes were aspects of seizure occurrence, quality of life, mood, anxiety, distress, symptoms, psychosocial functioning, clinical global change, satisfaction with treatment, quality-adjusted life-years, costs and cost-effectiveness. RESULTS: In total, 698 patients were screened and 368 were randomised (standardised medical care alone, n = 182; and cognitive-behavioural therapy plus standardised medical care, n = 186). Primary outcome data were obtained for 85% of participants. An intention-to-treat analysis with multivariate imputation by chained equations revealed no significant between-group difference in dissociative seizure frequency at 12 months [standardised medical care: median of seven dissociative seizures (interquartile range 1-35 dissociative seizures); cognitive-behavioural therapy and standardised medical care: median of four dissociative seizures (interquartile range 0-20 dissociative seizures); incidence rate ratio 0.78, 95% confidence interval 0.56 to 1.09; p = 0.144]. Of the 16 secondary outcomes analysed, nine were significantly better in the arm receiving cognitive-behavioural therapy at a p-value < 0.05, including the following at a p-value ≤ 0.001: the longest dissociative seizure-free period in months 7-12 inclusive post randomisation (incidence rate ratio 1.64, 95% confidence interval 1.22 to 2.20; p = 0.001); better psychosocial functioning (Work and Social Adjustment Scale, standardised treatment effect -0.39, 95% confidence interval -0.61 to -0.18; p < 0.001); greater self-rated and clinician-rated clinical improvement (self-rated: standardised treatment effect 0.39, 95% confidence interval 0.16 to 0.62; p = 0.001; clinician rated: standardised treatment effect 0.37, 95% confidence interval 0.17 to 0.57; p < 0.001); and satisfaction with treatment (standardised treatment effect 0.50, 95% confidence interval 0.27 to 0.73; p < 0.001). Rates of adverse events were similar across arms. Cognitive-behavioural therapy plus standardised medical care produced 0.0152 more quality-adjusted life-years (95% confidence interval -0.0106 to 0.0392 quality-adjusted life-years) than standardised medical care alone. The incremental cost-effectiveness ratio (cost per quality-adjusted life-year) for cognitive-behavioural therapy plus standardised medical care versus standardised medical care alone based on the EuroQol-5 Dimensions, five-level version, and imputed data was £120,658. In sensitivity analyses, incremental cost-effectiveness ratios ranged between £85,724 and £206,067. Qualitative and quantitative process evaluations highlighted useful study components, the importance of clinical experience in treating patients with dissociative seizures and potential benefits of our multidisciplinary care pathway. LIMITATIONS: Unlike outcome assessors, participants and clinicians were not blinded to the interventions. CONCLUSIONS: There was no significant additional benefit of dissociative seizure-specific cognitive-behavioural therapy in reducing dissociative seizure frequency, and cost-effectiveness over standardised medical care was low. However, this large, adequately powered, multicentre randomised controlled trial highlights benefits of adjunctive dissociative seizure-specific cognitive-behavioural therapy for several clinical outcomes, with no evidence of greater harm from dissociative seizure-specific cognitive-behavioural therapy. FUTURE WORK: Examination of moderators and mediators of outcome. TRIAL REGISTRATION: Current Controlled Trials ISRCTN05681227 and ClinicalTrials.gov NCT02325544. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 43. See the NIHR Journals Library website for further project information.

UR - http://www.scopus.com/inward/record.url?scp=85110077458&partnerID=8YFLogxK

U2 - 10.3310/hta25430

DO - 10.3310/hta25430

M3 - Article

VL - 25

SP - vii-144

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 43

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454